American Association for Cancer Research
Browse
- No file added yet -

Supplementary Fig. S3 from SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis

Download (113.3 kB)
journal contribution
posted on 2023-03-31, 23:25 authored by Lulu Farhana, Marcia I. Dawson, Liping Xu, Jan-Hermen Dannenberg, Joseph A. Fontana
Supplementary Fig. S3 from SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule–mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis

History

ARTICLE ABSTRACT

We previously found that the adamantyl-substituted retinoid-related molecules bind to the small heterodimer partner (SHP) as well as the Sin3A complex. In this report, we delineated the role of SHP and the Sin3A complex in 4-[3′-(1-adamantyl)-4′-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC)–mediated inhibition of cell growth and apoptosis. We examined the effect of loss of SHP and Sin3A expression in a number of cell types on 3-Cl-AHPC–mediated growth inhibition and apoptosis induction, 3-Cl-AHPC–mediated nuclear factor-κB (NF-κB) activation, and 3-Cl-AHPC–mediated increase in c-Fos and c-Jun expression. We found that loss of SHP or Sin3A expression, while blocking 3-Cl-AHPC–mediated apoptosis, had little effect on 3-Cl-AHPC inhibition of cellular proliferation. We have previously shown that 3-Cl-AHPC–mediated NF-κB activation is necessary for apoptosis induction. We have now shown that 3-Cl-AHPC–enhanced c-Fos and c-Jun expression is also essential for maximal 3-Cl-AHPC–mediated apoptosis. 3-Cl-AHPC induction of c-Fos and c-Jun expression as well as NF-κB activation was dependent on SHP protein levels. In turn, SHP levels are regulated by Sin3A because ablation of Sin3A resulted in a decrease in SHP expression. Thus, SHP and Sin3A play an important role in adamantyl-substituted retinoid-related induction of cellular apoptosis. [Mol Cancer Ther 2009;8(6):1625–35]

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC